My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
September 2012
Policy and Advocacy
Action Needed to Address Resistance, Spur R&D, Expand Immunizations

In a recent letter (PDF), the Society urged the Department of Health and Human Services to take several actions aimed at combating antimicrobial resistance, spurring the development of new antibiotics and diagnostics, and expanding immunizations. The recommendations build on language, requested by IDSA, contained in a funding bill passed by the Senate Appropriations Committee earlier this year.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Hospitals Required to Report HCW Influenza Vaccination Data in 2013
C. difficile Updates, Related Sessions at IDWeek
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
CMS to Include Maintenance of Certification in Incentive Program
Global ID
Thai HIV Vaccine Trial Yields More News
The Role of HIV-Related Stigma in Maternal Care in Kenya
HIV’s Impact on Men Who Have Sex with Men
Policy and Advocacy
IDSA Issues Updated Influenza Principles for U.S. Action
IDSA, HIVMA Urge Congress to Protect Public Health Funding
IDSA Offers Recommendations for Antibiotic Clinical Trial Designs
Action Needed to Address Resistance, Spur R&D, Expand Immunizations
Your Colleagues
Check Out “My IDSA” for Latest Member News
Top Stories
From the President: Volunteers Are Critical to IDSA’s Work
Updated Guideline on Group A Streptococcal Pharyngitis Now Online
EIN Update: West Nile Cases Underscore Lack of Treatment Data
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.